These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 36695364)
1. Are we ready to RESPOND that the question of abacavir's role in cardiovascular disease events is settled? Fichtenbaum CJ; Mallon P AIDS; 2023 Mar; 37(3):541-543. PubMed ID: 36695364 [No Abstract] [Full Text] [Related]
2. Abacavir and increased risk of myocardial infarction. Post FA; Campbell LJ Lancet; 2008 Sep; 372(9641):803; author reply 804-5. PubMed ID: 18774412 [No Abstract] [Full Text] [Related]
3. Abacavir and myocardial infarctions: the benefit of doubt? Behrens GM AIDS; 2011 Oct; 25(16):2043-5. PubMed ID: 21997489 [No Abstract] [Full Text] [Related]
4. Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk. Sinn K; Richardson R; Carr A AIDS; 2010 Sep; 24(15):2403-5. PubMed ID: 20647907 [TBL] [Abstract][Full Text] [Related]
5. Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study. De Luca A; de Gaetano Donati K; Cozzi-Lepri A; Colafigli M; De Curtis A; Capobianchi MR; Antinori A; Giacometti A; Magnani G; Vullo V; Cauda R; Iacoviello L; d'Arminio Monforte A; J Acquir Immune Defic Syndr; 2012 Jul; 60(3):e98-101. PubMed ID: 22728753 [No Abstract] [Full Text] [Related]
6. CROI 2009: a few key presentations on antiretroviral therapy. Gallant JE AIDS Read; 2009 Apr; 19(4):129-30, C3. PubMed ID: 19388179 [No Abstract] [Full Text] [Related]
7. 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections. Linde M Posit Living; 2002; 11(3):8-9, 16, 44. PubMed ID: 12035759 [No Abstract] [Full Text] [Related]
8. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use. Boyle BA; Cohen CJ; DeJesus E; Elion R; Frank I; Moyle GJ; Sax PE AIDS Read; 2009 Apr; 19(4):158-60. PubMed ID: 19388184 [No Abstract] [Full Text] [Related]
9. Comparing implications of cardiovascular risk of abacavir and integrase inhibitors: why scientific community is confused and timid? Guaraldi G; Milic J AIDS; 2023 May; 37(6):1005-1008. PubMed ID: 37017023 [No Abstract] [Full Text] [Related]
10. Abacavir's trials and tribulations. Gilden D GMHC Treat Issues; 1998 Nov; 12(11):1-3. PubMed ID: 11365905 [TBL] [Abstract][Full Text] [Related]
11. Abacavir and cardiovascular risk: reviewing the evidence. Costagliola D; Lang S; Mary-Krause M; Boccara F Curr HIV/AIDS Rep; 2010 Aug; 7(3):127-33. PubMed ID: 20521126 [TBL] [Abstract][Full Text] [Related]
12. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again. Sax PE J Watch AIDS Clin Care; 2009 Oct; 21(10):81. PubMed ID: 20458812 [No Abstract] [Full Text] [Related]
13. Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role? Marchetti G; Casana M; Tincati C; Bellistrì GM; Monforte Ad Clin Infect Dis; 2008 Dec; 47(11):1495-6. PubMed ID: 18986270 [No Abstract] [Full Text] [Related]
14. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus. Schafer JJ; Short WR; Squires KE Pharmacotherapy; 2010 Oct; 30(10):1072-83. PubMed ID: 20874044 [TBL] [Abstract][Full Text] [Related]
15. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. Marcus JL; Neugebauer RS; Leyden WA; Chao CR; Xu L; Quesenberry CP; Klein DB; Towner WJ; Horberg MA; Silverberg MJ J Acquir Immune Defic Syndr; 2016 Apr; 71(4):413-9. PubMed ID: 26536316 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation. Alvarez A; Orden S; Andújar I; Collado-Diaz V; Núñez-Delgado S; Galindo MJ; Estrada V; Apostolova N; Esplugues JV AIDS; 2017 Aug; 31(13):1781-1795. PubMed ID: 28537935 [TBL] [Abstract][Full Text] [Related]
17. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study). Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469 [No Abstract] [Full Text] [Related]
19. Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject. Rossotti R; Maggioni M; Merli M; Orcese C; Iavarone M; Puoti M AIDS; 2018 Jul; 32(12):1727-1729. PubMed ID: 30001246 [No Abstract] [Full Text] [Related]
20. Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient. de la Rosa R; Harris M; Uyeda L; Goodison K; Keown P; Montaner JS AIDS; 2004 Feb; 18(3):578-9. PubMed ID: 15090818 [No Abstract] [Full Text] [Related] [Next] [New Search]